<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566915</url>
  </required_header>
  <id_info>
    <org_study_id>15-0067</org_study_id>
    <nct_id>NCT02566915</nct_id>
  </id_info>
  <brief_title>Effects of Exhalation Valve on the Lack of Air and Exercise Tolerance in Patients With COPD</brief_title>
  <official_title>Effects of Expiratory Positive Airway Pressure on Dyspnea and Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of the application of Expiratory
      Positive Airway Pressure (EPAP) on Dynamic Hyperinflation, dyspnea and exercise tolerance in
      patients with Chronic Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially will be collected clinical and anthropometric data of the participants, and they
      are packaged in self-evaluation form. The evaluation of pulmonary function at rest
      (spirometry, body plethysmography and lung diffusion capacity for carbon monoxide) will be
      rescued from patient charts. When carried out for over six months, will be repeated by the
      researchers. Patients will conduct incremental CPET of 5-10W / min limited by symptoms (FEV1
      &lt;1L - 5W or FEV1&gt; 1L - 10W) (Visit 1). After a period of 2-7 days the CPET will be performed
      submaximal with 75% of the peak load reached in the incremental CPET (visits 2 and 3). The
      application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be
      randomized with the help of opaque envelopes to be given in one visit. During the visit
      without EPAP will be maintained using the facial mask applied without resistance. IC serial
      measurements will be carried out before, during and immediately after the exercise.
      Participants will be instructed to maintain the use of long-acting bronchodilator as
      prescribed by the medical assistant usually before the methodological stages of the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased Inspiratory Capacity (IC) through dynamic changes in lung volumes</measure>
    <time_frame>1 year</time_frame>
    <description>This technique assumes that the TLC remains unchanged during exercise, even in patients with COPD: thus, changes in IC will reflect in proportional changes in end-expiratory lung volume (EELV). The validity, reproducibility and sensitivity to these interventions have been demonstrated by this technique in patients with COPD, showing a variety of functional abnormalities.
Before the test, the patients will be familiar with this technique by performing IC maneuvers. They will be instructed to breathe normally during exercise and then, through verbal commands, will conduct a deep breath followed by a relaxed expiration. During inspiration, patients will be encouraged to make every effort.
IC maneuvers are performed during the rest period are obtained until at least two reproducible efforts, namely within 10% of the highest acceptable value. After that, measurements of IC will be held every two minutes until exhaustion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased exercise tolerance submaximal CPET</measure>
    <time_frame>1 year</time_frame>
    <description>To assess exercise tolerance we will compare the final time the two submaximal CPET (with EPAP and without EPAP). In each test, the patient will be encouraged to achieve maximum tolerance and will be instructed to stop the test in the exhaust.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased dyspnea submaximal CPET</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the sensation of dyspnea the year we will be using the modified Borg scale. This measurement will be held every two minutes during the two submaximal CPET (with EPAP and without EPAP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>CPET submaximal without EPAP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 &lt;1L-5W or FEV1&gt; 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPET submaximal with EPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 &lt;1L-5W or FEV1&gt; 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPET submaximal with EPAP</intervention_name>
    <description>The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.</description>
    <arm_group_label>CPET submaximal with EPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically stable patients without exacerbation of signs in the eight weeks preceding
             the study

          -  making use of drug therapy (long-acting bronchodilators)

          -  able to perform the exercise on the bike

          -  without other comorbidities that compromise the results exercise

          -  sign the Informed Consent

        Exclusion Criteria:

          -  associated heart diseases

          -  diagnosis of asthma

          -  Oxygen therapy use

          -  SpO2 &lt;85% at rest

          -  use of oral corticosteroids or antihistamines

          -  use of artificial airway

          -  musculoskeletal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danilo C Berton</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCPA/UFRGS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marli M Knorst</last_name>
    <role>Study Chair</role>
    <affiliation>HCPA/UFRGS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariane B Monteiro</last_name>
    <role>Study Chair</role>
    <affiliation>IPA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo José Z Teixeira</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dulciane N Paiva</last_name>
    <role>Study Chair</role>
    <affiliation>University of Santa Cruz do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dannuey M Cardoso</last_name>
    <role>Study Chair</role>
    <affiliation>University of Santa Cruz do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.scielo.br/pdf/bjmbr/v32n6/3179c.pdf</url>
    <description>Reference values for lung function testes. I.Static volumes.</description>
  </link>
  <link>
    <url>http://www.jornaldepneumologia.com.br/pdf/suple_124_40_dpoc_completo_finalimpresso.pdf</url>
    <description>II Consenso Brasileiro sobre Doença Pulmonar Obstrutiva Crônica</description>
  </link>
  <link>
    <url>http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-51502012000300018</url>
    <description>Analysis of chest radiography of individuals with COPD and its correlation with functional testing</description>
  </link>
  <link>
    <url>http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1806-37132012000100004</url>
    <description>Dynamic hyperinflation during treadmill exercise testing in patients with moderate to severe COPD</description>
  </link>
  <link>
    <url>http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-51502012000400004</url>
    <description>Determining anaerobic threshold through heart rate variability in patients with COPD during cycloergometer exercise</description>
  </link>
  <link>
    <url>http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1517-86922012000500002&amp;lng=en&amp;nrm=iso&amp;tlng=en</url>
    <description>Comparison of the physiological variables in the six-minute walk test and stair-climbing test in patients with chronic obstructive pulmonary disease</description>
  </link>
  <link>
    <url>http://www.scielo.br/pdf/jbpneu/v34n12/v34n12a05.pdf</url>
    <description>Validation of the Modified Pulmonary Functional Status and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients with chronic obstructive pulmonary disease</description>
  </link>
  <reference>
    <citation>Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65. doi: 10.1164/rccm.201204-0596PP. Epub 2012 Aug 9. Review.</citation>
    <PMID>22878278</PMID>
  </reference>
  <reference>
    <citation>O'Donnell DE, Gebke KB. Activity restriction in mild COPD: a challenging clinical problem. Int J Chron Obstruct Pulmon Dis. 2014 Jun 4;9:577-88. doi: 10.2147/COPD.S62766. eCollection 2014. Review.</citation>
    <PMID>24940054</PMID>
  </reference>
  <reference>
    <citation>Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014 Feb 15;9:187-201. doi: 10.2147/COPD.S38934. eCollection 2014. Review.</citation>
    <PMID>24600216</PMID>
  </reference>
  <reference>
    <citation>Silveira L, Teixeira PJ, da Costa CC, de Souza RM, Merola PK, Colombo C, Marques RD, Berton DC. The relationship between fat-free mass index and pulmonary hyperinflation in COPD patients. Respirology. 2014 Nov;19(8):1204-8. doi: 10.1111/resp.12406.</citation>
    <PMID>25302758</PMID>
  </reference>
  <reference>
    <citation>Pessoa IM, Costa D, Velloso M, Mancuzo E, Reis MA, Parreira VF. Effects of noninvasive ventilation on dynamic hiperinflation of patients with COPD during activities of daily living with upper limbs. Rev Bras Fisioter. 2012 Jan-Feb;16(1):61-7. English, Portuguese.</citation>
    <PMID>22441230</PMID>
  </reference>
  <reference>
    <citation>Andersen JB, Qvist J, Kann T. Recruiting collapsed lung through collateral channels with positive end-expiratory pressure. Scand J Respir Dis. 1979 Oct;60(5):260-6.</citation>
    <PMID>392747</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes. Eur Respir J. 2005 Sep;26(3):511-22. Review.</citation>
    <PMID>16135736</PMID>
  </reference>
  <reference>
    <citation>Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.</citation>
    <PMID>7154893</PMID>
  </reference>
  <reference>
    <citation>Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Mar;153(3):967-75.</citation>
    <PMID>8630581</PMID>
  </reference>
  <reference>
    <citation>Yan S, Kaminski D, Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997 Jul;156(1):55-9.</citation>
    <PMID>9230726</PMID>
  </reference>
  <reference>
    <citation>O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1557-65.</citation>
    <PMID>9817708</PMID>
  </reference>
  <reference>
    <citation>Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 Jun;85(6):751-8.</citation>
    <PMID>6723384</PMID>
  </reference>
  <results_reference>
    <citation>Monteiro MB, Berton DC, Moreira MA, Menna-Barreto SS, Teixeira PJ. Effects of expiratory positive airway pressure on dynamic hyperinflation during exercise in patients with COPD. Respir Care. 2012 Sep;57(9):1405-12. doi: 10.4187/respcare.01481. Epub 2012 Feb 17.</citation>
    <PMID>22348429</PMID>
  </results_reference>
  <results_reference>
    <citation>Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999 Jun;32(6):729-37.</citation>
    <PMID>10412551</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Donnell DE, Sanii R, Giesbrecht G, Younes M. Effect of continuous positive airway pressure on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal exercise. Am Rev Respir Dis. 1988 Nov;138(5):1185-91.</citation>
    <PMID>3059891</PMID>
  </results_reference>
  <results_reference>
    <citation>Nicolini A, Merliak F, Barlascini C. Use of positive expiratory pressure during six minute walk test: results in patients with moderate to severe chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013 Mar 14;8(1):19. doi: 10.1186/2049-6958-8-19.</citation>
    <PMID>23497658</PMID>
  </results_reference>
  <results_reference>
    <citation>Soares SM, Oliveira RA, Franca SA, Rezende SM, Dragosavac D, Kacmarek RM, Carvalho CR. Continuous positive airway pressure increases inspiratory capacity of COPD patients. Respirology. 2008 May;13(3):387-93. doi: 10.1111/j.1440-1843.2008.01263.x.</citation>
    <PMID>18399861</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

